Some genetic mutations can significantly alter the choice of treatment or signal that a cancer is more likely to become resistant to a treatment. In colorectal cancers, mutations in the KRAS genes may signal that a patient will not respond to certain drugs targeting the EGFR pathway such as cetuximab or panitumumab.
SRSF2 alterations have not been detected in colon cancer. IDH2 and SF3B1 mutations have been identified in colon cancer at low frequencies; they have not been associated with resistance to drugs targeting the EGFR pathway to date.
Learn more about targeting KRAS.
Medscape © 2023 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Winston W. Tan, Evelyn S. Marienberg. Fast Five Quiz: Precision Medicine in Cancer - Medscape - Jan 06, 2023.